| Zugriffe | |
|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 287 |
| April 2025 | Mai 2025 | Juni 2025 | Juli 2025 | August 2025 | September 2025 | Oktober 2025 | |
|---|---|---|---|---|---|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 0 | 22 | 9 | 19 | 4 | 13 | 15 |
| Zugriffe | |
|---|---|
| 2021_Frost_etal.pdf | 217 |
